--- title: "The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts" type: "News" locale: "en" url: "https://longbridge.com/en/news/285739725.md" description: "The Chemours Company (NYSE:CC) reported a surprise loss of $0.19 per share on revenues of $1.4 billion, leading to a 17% drop in stock price. Analysts have adjusted their forecasts, predicting revenues of $6.02 billion and earnings of $1.21 per share for 2026, down from previous estimates. Despite the earnings downgrade, the price target was raised by 9.8% to $24.89, indicating a positive long-term outlook. Chemours is expected to grow at a rate similar to the industry average, with a projected annual revenue growth of 4.6%." datetime: "2026-05-08T14:04:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285739725.md) - [en](https://longbridge.com/en/news/285739725.md) - [zh-HK](https://longbridge.com/zh-HK/news/285739725.md) --- # The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts It's been a mediocre week for **The Chemours Company** (NYSE:CC) shareholders, with the stock dropping 17% to US$22.41 in the week since its latest quarterly results. Things were not great overall, with a surprise (statutory) loss of US$0.19 per share on revenues of US$1.4b, even though the analysts had been expecting a profit. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. NYSE:CC Earnings and Revenue Growth May 8th 2026 Taking into account the latest results, the consensus forecast from Chemours' nine analysts is for revenues of US$6.02b in 2026. This reflects an okay 3.5% improvement in revenue compared to the last 12 months. Earnings are expected to improve, with Chemours forecast to report a statutory profit of US$1.21 per share. Before this earnings report, the analysts had been forecasting revenues of US$6.04b and earnings per share (EPS) of US$1.58 in 2026. The analysts seem to have become more bearish following the latest results. While there were no changes to revenue forecasts, there was a pretty serious reduction to EPS estimates. Check out our latest analysis for Chemours Despite cutting their earnings forecasts,the analysts have lifted their price target 9.8% to US$24.89, suggesting that these impacts are not expected to weigh on the stock's value in the long term. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Chemours analyst has a price target of US$30.00 per share, while the most pessimistic values it at US$17.00. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view. Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. For example, we noticed that Chemours' rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 4.6% growth to the end of 2026 on an annualised basis. That is well above its historical decline of 1.5% a year over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 5.2% per year. So while Chemours' revenues are expected to improve, it seems that it is expected to grow at about the same rate as the overall industry. ## The Bottom Line The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving. Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Chemours going out to 2028, and you can see them free on our platform here.. That said, it's still necessary to consider the ever-present spectre of investment risk. **We've identified 2 warning signs** with Chemours (at least 1 which doesn't sit too well with us) , and understanding these should be part of your investment process. ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [CC.US](https://longbridge.com/en/quote/CC.US.md) ## Related News & Research - [Chemours Announces Second Quarter Dividend | CC Stock News](https://longbridge.com/en/news/285296843.md) - [11:26 ETUn estudio identifica la vía para reducir emisiones acumuladas de refrigerantes de automoción en toda Europa](https://longbridge.com/en/news/286286663.md) - [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md) - [Earnings Beat: Deepak Nitrite Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286980047.md) - [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md)